Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI
Giorgio Brembilla(Vita-Salute San Raffaele University), Francesco De Cobelli(Vita-Salute San Raffaele University), Valentina Tateo(Vita-Salute San Raffaele University), Salvatore Lavalle(Università degli Studi di Enna Kore), Gianpiero Cardone(IRCCS Ospedale San Raffaele), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Francesco Giganti(University College Hospital), Alberto Martini(The University of Texas MD Anderson Cancer Center), Andrea Del Prete(University of Trento), Antonio Cigliola(Vita-Salute San Raffaele University), A. Messina(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Montorsi(Vita-Salute San Raffaele University), Renato Pennella(Vita-Salute San Raffaele University), Giuseppina Calareso(Fondazione IRCCS Istituto Nazionale dei Tumori), Marco Bandini(IRCCS Ospedale San Raffaele), Andrea Necchi(Vita-Salute San Raffaele University), Marco Moschini(Vita-Salute San Raffaele University), Chiara Mercinelli, Patrizia Giannatempo(Fondazione IRCCS Istituto Nazionale dei Tumori), Emanuele Crupi(The University of Texas MD Anderson Cancer Center), Michele Cosenza(Vita-Salute San Raffaele University), Giuseppe Basile(Vita-Salute San Raffaele University), Damiano Alfio Patanè(Vita-Salute San Raffaele University), Tommaso Russo(Vita-Salute San Raffaele University)
Cited by 31
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k